← Patent-cliff monitor small molecule TALZENNA TALAZOPARIB TOSYLATE
Loss of exclusivity October 2031 latest FDA-listed patent expiry
Company Pfizer → See this company's full patent-cliff portfolio Drug detail Brand name TALZENNA Active ingredient TALAZOPARIB TOSYLATE Strength EQ 0.1MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval June 2023 Marketing status DISCN
Listed patents Patent Expires Type 10189837 October 2031 substance, product 8735392 October 2031 substance, product 9820985 July 2029 use U-2437 10780088 July 2029 use U-3651 8012976 July 2029 substance, product 8420650 July 2029 substance, product
Regulatory exclusivity Code Expires I-920 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.